Microcrystal and diseases

Home → Research → Research teams → Microcrystal & diseases

Microcrystal and diseases

Three kinds of crystals are responsible of rheumatic diseases: monosodium urate crystals give rise to gout, calcium pyrophosphate (CPP) crystals to chondrocalcinosis or CPP deposition disease and basic phosphate calcium crystals to hydroxyapatite rheumatism.  Gout and CPP disease are the most frequent adult inflammatory arthritis. All three crystals induce a self-limiting acute inflammatory arthritis which is an interleukin (IL)-1β driven reaction. IL-1β production is a two-step process involving NF-κB and inflammasome NLRP3 activation.

We aim to understand how crystals are formed, how crystals trigger inflammation and how this inflammation self-resolves.

We combine in vitro, in vivo and translational researches using mouse models and human samples collected in crystal-related disease cohorts. We use infrared-spectroscopy, electronic microscopy and synchrotron to characterize different crystals.

We focus on the role of metabolism switch, production of reactive oxygen species and crystal-cell membrane interaction in crystal-induced inflammation. We have identified new targets in calcium-containing crystal diseases and assess their effects in clinical trials.

We organize the annual European Crystal Network meeting that permits multidisciplinary approach and collaboration in crystal-related diseases.

We set up a partnership between Paris 7 University and Ho-Chi-Minh University and create the French-Vietnamese center dedicated to gout management based on basic, functional genomics and therapeutical approaches.

Researchers

EA Korng
PU-PH

ZOUALI Moncef
DR

BARDIN Thomas
PU PH

LIOTE Frédéric
PU PH

RICHETTE Pascal
PU-PH


F. Renaudin Thèse 2ème annéee
A. Gauffenic M2
M. Jalabert M2

 

 

 

Publications

Bardin T, Bouée S, Clerson P, Chalès G, Flipo RM, Lioté F, Perez V, Poiraud T, Schaeverbeke T, Richette P. Prevalence of Gout in the Adult Population of France. Arthritis Care Res (Hoboken). 2016 Feb;68(2):261-6.

Bardin T, Chalès G, Pascart T, Flipo RM, Korng Ea H, Roujeau JC, Delayen A, Clerson P. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment. Joint Bone Spine. 2016 May;83(3):314-7.

Bardin T, Keenan RT, Khanna PP, Kopicko J, Fung M, Bhakta N, Adler S, Storgard C, Baumgartner S, So A. Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study). Ann Rheum Dis. 2017 May;76(5):811-820. 

Ben Kilani MS, Achour Y, Perea J, Cornelis F, Bardin T, Chaudru V, Maalej A, Petit-Teixeira E. Characterization of copy number variants for CCL3L1 gene in rheumatoid arthritis for French trio families and Tunisian cases and controls. Clin Rheumatol. 2016 Jan 4. [Epub ahead of print] PMID:26728148

Cooper C, Bartin T, ML, Cacoub P, Caminis J, Civitelli R, Cutolo M, Dere W. Balancing benefits and risks of glucocorticoids in rheumatic diseases and other inflammatory joint disorders: new insights from emerging data. An expert consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Aging Clin Exp Res. 2016 Jan8 [Epub ahead of print] PMID: 26746234

Juge PA, Truchetet ME, Pillebout E, Ottaviani S, Vigneau C, Loustau C, Cornec D, Pascart T, Snanoudj R, Bailly F, Cornec-Le Gall E, Schaeverbeke T, Saraux A, Dieudé P, Flipo RM, Richette P, Lioté F, Bardin T, Chalès G, Ea HK. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2016 Nov 4. pii: S1297-319X(16)30175-0. 

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, Engel B, Flader C, Kay J, Matsuoka M, Perez-Ruiz F, da Rocha Castelar-Pinheiro G, Saag K, So A, Vazquez Mellado J, Weisman M, Westhoff TH, Yamanaka H, Braun J. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2016 Apr;76(4):632-638.

Lahaye C, Soubrier M, Mulliez A, Bardin T, Cantagrel A, Combe B, Dougados M, Flipo RM, Le Loët X, Shaeverbeke T, Ravaud P, Mariette X, Gottenberg JE; French Society of Rheumatology. Effectiveness and safety of abatacept in elderly patients with rheumatoid arthritis enrolled in the French Society of Rheumatology’s ORA registry. Rheumatology (Oxford). 2016 May;55(5):874-82.

Malbos S, Ureña-Torres P, Bardin T, Ea HK. Sodium thiosulfate is effective in calcific uremic arteriolopathy complicating chronic hemodialysis. Joint Bone Spine. 2016 Jan;83(1):89-92.

Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz F, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42.

Richette P, Poitou C, Manivet P, Denis J, Bouillot JL, Clément K, Oppert JM, Bardin T. Weight Loss, Xanthine Oxidase, and Serum Urate Levels: A Prospective Longitudinal Study of Obese Patients. Arthritis Care Res (Hoboken). 2016 Jul;68(7):1036-42.

Salmon JH, Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, Houvenagel E, Gaudin P, Loeuille D, Rist S, Dougados M, Sibilia J, Le Loët X, Meyer O, Solau-Gervais E, Marcelli C, Bardin T, Pane I, Baron G, Perrodeau E, Mariette X; all the investigators of the ORA registry and the French Society of Rheumatology. Predictive risk factors of serious infections in patients with rheumatoid arthritis treated with abatacept in common practice: results from the Orencia and Rheumatoid Arthritis (ORA) registry. Ann Rheum Dis. 2016 Jun;75(6):1108-13

Zouali, M. (2016). The emerging roles of B cells as partners and targets in periodontitis. Autoimmunity, 1-10.

Zouali, M., and Tsay, G. (2016). Developing connections amongst B lymphocytes and deregulated pathways in autoimmunity. Molecular Medicine 22. doi: 10.2119/molmed.2016.00206

Juge, Pierre-Antoine; Truchetet, Marie-Elise; Pillebout, Evangeline; Ottaviani, Sebastien; Vigneau, Cecile; Loustau, Clotilde; Cornec, Divi; Pascart, Tristan; Snanoudj, Renaud; Bailly, Florian; Gall, Emilie Cornec-Le; Schaeverbeke, Thierry; Saraux, Alain; Dieude, Philippe; Flipo, Rene-Marc; Richette, Pascal; Liote, Frederic; Bardin, Thomas; Chales, Gerard; Ea, Hang-Korng. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. JOINT BONE SPINE. 2017;84(5):595-59

Maravic, Milka; Hincapie, Natalia; Pilet, Simon; Flipo, Rene-Marc; Liote, Frederic. Persistent clinical inertia in gout in 2014: An observational French longitudinal patient database study. Joint, bone, spine : revue du rhumatisme. 2017. 10.1016/j.jbspin.2017.03.013

Nasi, Sonia; Ea, Hang-Korng; So, Alexander; Busso, Nathalie. Revisiting the Role of Interleukin-1 Pathway in Osteoarthritis: Interleukin-1 alpha and-1 beta, and NLRP3 Inflammasome Are Not Involved in the Pathological Features of the Murine Menisectomy Model of Osteoarthritis. FRONTIERS IN PHARMACOLOGY. 2017 ;8. 10.3389/fphar.2017.00282

Richette, Pascal; Doherty, Michael; Pascual, Eliseo; Bardin, Thomas. Response: Renal dosing of allopurinol results in suboptimal gout care by T Neogi et al.. Annals of the rheumatic diseases. 2017;76(1):e2-e2

Richette, Pascal; Doherty, Michael; Pascual, Eliseo; Bardin, Thomas. SUA levels should not be maintained <3 mg/dL for several years. Response to ‘EULAR gout treatment guidelines by Richette et al: uric acid and neurocognition by Singh et al’. Annals of the rheumatic diseases. 2017. 10.1136/annrheumdis-2017-211423

Ebstein, E.; Ea, H-K  Spontaneous resolution of Epstein-Barr virus-induced haemophagocytic lymphohistiocytosis in Still’s disease treated by tocilizumab: a case report. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY. 2018;47(1):84-85

Navarro-Compan, Victoria; Ramiro, Sofia; Landewe, Robert; Dougados, Maxime; Miceli-Richard, Corinne; Richette, Pascal; van der Heijde, Desiree. In patients with axial spondyloarthritis, inflammation on MRI of the spine is longitudinally related to disease activity only in men: 2 years of the axial spondyloarthritis DESIR cohort.  Annals of the rheumatic diseases. 2018;77(3):470-472

Terreaux, William; Masson, Claire; Eschard, Jean-Paul; Bardin, Thomas; Constantin, Arnaud; Le Dantec, Loic; Marcelli, Christian; Perdriger, Aleth; Scotto Di Fazano, Claire; Wendling, Daniel; Sibilia, Jean; Morel, Jacques; Salmon, Jean-Hugues. Incidence of paradoxical reactions in patients treated with tocilizumab for rheumatoid arthritis: Data from the French registry REGATE. Joint, bone, spine : revue du rhumatisme. 2018;85(1):53-57

Contacts

Osteoporosis

Corinne
COLLET

+33 (0)1 49 95 64 35
corinne.collet@inserm.fr

Tumor & microenvironment

Sylvain
PROVOT

+33 (0)1 49 95 64 02
sylvain.provot@inserm.fr

Osteoarthritis

Martine
COHEN-SOLAL

+33 (0)1 49 95 63 57
martine.cohen-solal@inserm.fr

Microcrystal & diseases

Korng
EA

+33 (0)1 49 95 86 42
korng.ea@inserm.fr

id, nunc ante. ut pulvinar ut accumsan et, amet, tempus